中国全科医学 ›› 2020, Vol. 23 ›› Issue (6): 747-754.DOI: 10.12114/j.issn.1007-9572.2019.00.400
潘健将,徐志杰,祝悦,方力争*
出版日期:
2020-02-20
发布日期:
2020-02-20
PAN Jianjiang,XU Zhijie,ZHU Yue,FANG Lizheng*
Published:
2020-02-20
Online:
2020-02-20
摘要: 背景 不合理的多重用药,特别是在老年人群中,会带来严重后果,包括药物不良反应、疾病、残疾、住院甚至死亡。处方精简通过逐渐减少或停止用药,尽量减少多药使用,最终改善患者的预后。目的 检索并分析2003—2018年Web of Science收录的关于处方精简的原始研究类文献,探讨文献分布以及研究热点。方法 2018-10-10,在Web of Sciences数据库中采用主题词检索的方式进行检索,检索式如下:主题=(“deprescribing”)OR主题=(“deprescribe”),检索年限选择2003—2018年。首先将所检索文献根据纳入标准进行筛选,然后通过EndNote 8.0及Web of Science网站中的分析检索工具对纳入文献进行文献计量学分析。结果 本研究纳入70篇原始研究类文献。2012—2014年共发表文章2篇(2.9%);2015年发文量开始增长,全年发表5篇(7.1%);2016年1月—2018年10月,发文量快速增长〔共计63篇(90.0%)〕。发文量最大的期刊为BMJ Open和European Journal of Hospital Pharmacy Science and Practice(各5篇),其中共有7种SCI期刊发文量≥3篇。BMC Medicine的影响因子(IF)最高(IF=9.08)。高被引(被引量≥7次)的文献有21篇。纳入的文献来自17个国家/地区,其中加拿大、澳大利亚、美国发文量最多。文献平均作者合作度为5.4,即每篇论文平均有5~6位作者;平均机构合作度为3.0,即每篇论文平均有3家机构参与研究。对文献的第一作者职业分布情况进行分析,结果显示大部分为临床药师、公共卫生领域学者和全科医生。纳入文献的研究学科主要是药剂学和内科学,其次是老年医学。结论 处方精简领域的研究虽然尚处于起步阶段,但是已经成为研究热点。2016年以后发文量快速增长,且主要集中在加拿大、澳大利亚、美国等国家。发表文献的第一作者主要为临床药师、公共卫生领域学者和全科医生。
[1]The United Nations.World population prospects,the 2017 revision[EB/OL].(2017-06-21) [2018-09-13].https://population.un.org/wpp/Publications/. [2]MORIN L,JOHNELL K,LAROCHE M L,et al.The epidemiology of polypharmacy in older adults:register-based prospective cohort study[J].Clin Epidemiol,2018,10:289-298.DOI:10.2147/CLEP.S153458. [3]SAHINOVIC M M,ELEVELD D J,MIYABE-NISHIWAKI T,et al.Pharmacokinetics and pharmacodynamics of propofol:changes in patients with frontal brain tumours[J].Br J Anaesth,2017,118(6):901-909.DOI:10.1093/bja/aex134. [4]Australian and new zealand society for geriatric medicine position statement abstract:prescribing in older people[J].Australas J Ageing,2018,37(4):313.DOI:10.1111/ajag.12577. [5]WOODWARD M C.Deprescribing:achieving better health outcomes for older people through reducing medications[J].Journal of Pharmacy Practice and Research,2003,33(4):323-328.DOI:10.1002/jppr2003334323. [6]SCHULING J,GEBBEN H,VEEHOF L J,et al.Deprescribing medication in very elderly patients with multimorbidity:the view of Dutch GPs.A qualitative study[J].BMC Fam Pract,2012,13:56.DOI:10.1186/1471-2296-13-56. [7]REEVE E,SHAKIB S,HENDRIX I,et al.Development and validation of the patients' attitudes towards deprescribing(PATD) questionnaire[J].Int J Clin Pharm,2013,35(1):51-56.DOI:10.1007/s11096-012-9704-5. [8]Ní CHRóINíN D,Ní CHRóINíN C,BEVERIDGE A.Factors influencing deprescribing habits among geriatricians[J].Age Ageing,2015,44(4):704-708.DOI:10.1093/ageing/afv028. [9]CONKLIN J,FARRELL B,WARD N,et al.Developmental evaluation as a strategy to enhance the uptake and use of deprescribing guidelines:protocol for a multiple case study[J].Implement Sci,2015,10:91.DOI:10.1186/s13012-015-0279-0. [10]FARRELL B,TSANG C,RAMAN-WILMS L,et al.What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners:a modified delphi process[J].PLoS One,2015,10(4):e0122246.DOI:10.1371/journal.pone.0122246. [11]LINDSAY J,DOOLEY M,MARTIN J,et al.The development and evaluation of an oncological palliative care deprescribing guideline:the ‘OncPal deprescribing guideline’[J].Support Care Cancer,2015,23(1):71-78.DOI:10.1007/s00520-014-2322-0. [12]REEVE E,ANDREWS J M,WIESE M D,et al.Feasibility of a patient-centered deprescribing process to reduce inappropriate use of proton pump inhibitors[J].Ann Pharmacother,2015,49(1):29-38.DOI:10.1177/1060028014558290. [13]AILABOUNI N J,NISHTALA P S,MANGIN D,et al.Challenges and enablers of deprescribing:a general practitioner perspective[J].PLoS One,2016,11(4):e0151066.DOI:10.1371/journal.pone.0151066. [14]AILABOUNI N J,NISHTALA P S,MANGIN D,et al.General practitioners' insight into deprescribing for the multimorbid older individual:a qualitative study[J].Int J Clin Pract,2016,70(3):261-276.DOI:10.1111/ijcp.12780. [15]ANDREASSEN L M,KJOME R L,S?LVIK U ?,et al.The potential for deprescribing in care home residents with type 2 diabetes[J].Int J Clin Pharm,2016,38(4):977-984.DOI:10.1007/s11096-016-0323-4. [16]BOLMSJ? B B,PALAGYI A,KEAY L,et al.Factors influencing deprescribing for residents in Advanced Care Facilities:insights from General Practitioners in Australia and Sweden[J].BMC Fam Pract,2016,17(1):152.DOI:10.1186/s12875-016-0551-7. [17]BRANDT N J.Optimizing medication use through deprescribing:tactics for this approach[J].J Gerontol Nurs,2016,42(1):10-14.DOI:10.3928/00989134-20151218-08. [18]HOKE L J,DILICH A S.The deprescribing of calcium supplements in a state operated developmental center:a 10-year longitudinal pilot study[J].International Journal of Developmental Disabilities,2016,62(1):3-10.DOI:10.1179/2047387714y.0000000056. [19]KOULADJIAN L,GNJIDIC D,REEVE E,et al.Health care practitioners' perspectives on deprescribing anticholinergic and sedative medications in older adults[J].Ann Pharmacother,2016,50(8):625-636.DOI:10.1177/1060028016652997. [20]LUYMES C H,VAN DER KLEIJ R M,POORTVLIET R K,et al.Deprescribing potentially inappropriate preventive cardiovascular medication:barriers and enablers for patients and general practitioners[J].Ann Pharmacother,2016,50(6):446-454.DOI:10.1177/1060028016637181. [21]MCKEAN M,PILLANS P,SCOTT I A.A medication review and deprescribing method for hospitalised older patients receiving multiple medications[J].Intern Med J,2016,46(1):35-42.DOI:10.1111/imj.12906. [22]MUDGE A,RADNEDGE K,KASPER K,et al.Effects of a pilot multidisciplinary clinic for frequent attending elderly patients on deprescribing[J].Aust Health Rev,2016,40(1):86-91.DOI:10.1071/AH14219. [23]PAGE A T,ETHERTON-BEER C D,CLIFFORD R M,et al.Deprescribing in frail older people——do doctors and pharmacists agree?[J].Res Social Adm Pharm,2016,12(3):438-449.DOI:10.1016/j.sapharm.2015.08.011. [24]PALAGYI A,KEAY L,HARPER J,et al.Barricades and brickwalls——a qualitative study exploring perceptions of medication use and deprescribing in long-term care[J].BMC Geriatr,2016,16:15.DOI:10.1186/s12877-016-0181-x. [25]POTTER K,FLICKER L,PAGE A,et al.Deprescribing in frail older people:a randomised controlled trial[J].PLoS One,2016,11(3):e0149984.DOI:10.1371/journal.pone.0149984. [26]REEVE E,LOW L F,HILMER S N.Beliefs and attitudes of older adults and carers about deprescribing of medications:a qualitative focus group study[J].Br J Gen Pract,2016,66(649):e552-560.DOI:10.3399/bjgp16X685669. [27]REEVE E,LOW L F,SHAKIB S,et al.Development and validation of the revised patients' attitudes towards deprescribing(rPATD) questionnaire:versions for older adults and caregivers[J].Drugs Aging,2016,33(12):913-928.DOI:10.1007/s40266-016-0410-1. [28]THOMPSON W,HOGEL M,LI Y,et al.Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care[J].J Am Med Dir Assoc,2016,17(7):673.e1-673.e4.DOI:10.1016/j.jamda.2016.04.020. [29]TURNER J P,EDWARDS S,STANNERS M,et al.What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals[J].BMJ Open,2016,6(3):e009781.DOI:10.1136/bmjopen-2015-009781. [30]WALSH K,KWAN D,MARR P,et al.Deprescribing in a family health team:a study of chronic proton pump inhibitor use[J].J Prim Health Care,2016,8(2):164-171.DOI:10.1071/HC15946. [31]ADAMS D,SAWHNEY I.Deprescribing of psychotropic medication in a 30-year-old man with learning disability[J].Eur J Hosp Pharm Sci Pract,2017,24(1):63-64.DOI:10.1136/ejhpharm-2016-001051. [32]AILABOUNI N,MANGIN D,NISHTALA P S.Deprescribing anticholinergic and sedative medicines:protocol for a Feasibility Trial(DEFEAT-polypharmacy) in residential aged care facilities[J].BMJ Open,2017,7(4):e013800.DOI:10.1136/bmjopen-2016-013800. [33]AILABOUNI N,TORDOFF J,MANGIN D,et al.Do residents need all their medications? A cross-sectional survey of RNs' views on deprescribing and the role of clinical pharmacists[J].J Gerontol Nurs,2017,43(10):13-20.DOI:10.3928/00989134-20170914-05. [34]ANDERSON K,FOSTER M,FREEMAN C,et al.Negotiating “unmeasurable harm and benefit”:perspectives of general practitioners and consultant pharmacists on deprescribing in the primary care setting[J].Qual Health Res,2017,27(13):1936-1947.DOI:10.1177/1049732316687732. [35]BAQIR W,HUGHES J,JONES T,et al.Impact of medication review,within a shared decision-making framework,on deprescribing in people living in care homes[J].Eur J Hosp Pharm Sci Pract,2017,24(1):30-33.DOI:10.1136/ejhpharm-2016-000900. [36]ETXEBERRIA A,IRIBAR J,HERNANDO J,et al.Deprescribing long-term treatments with bisphosphonates for osteoporosis in primary care in the Basque Country(Spain)[J].Gac Sanit,2017,31(1):35-39.DOI:10.1016/j.gaceta.2016.07.003. [37]FARRELL B,BLACK C,THOMPSON W,et al.Deprescribing antihyperglycemic agents in older persons:evidence-based clinical practice guideline[J].Can Fam Physician,2017,63(11):832-843. [38]FARRELL B,POTTIE K,THOMPSON W,et al.Deprescribing proton pump inhibitors:evidence-based clinical practice guideline[J].Can Fam Physician,2017,63(5):354-364. [39]FRIED T R,NIEHOFF K M,STREET R L,et al.Effect of the tool to reduce inappropriate medications on medication communication and deprescribing[J].J Am Geriatr Soc,2017,65(10):2265-2271.DOI:10.1111/jgs.15042. [40]GULLIFORD M,RAVINDRARAJAH R,HAMADA S,et al.Inception and deprescribing of statins in people aged over 80 years:cohort study[J].Age Ageing,2017,46(6):1001-1005.DOI:10.1093/ageing/afx100. [41]KUA C H,YEO C Y Y,CHAR C W T,et al.Nursing home team-care deprescribing study:a stepped-wedge randomised controlled trial protocol[J].BMJ Open,2017,7(5):e015293.DOI:10.1136/bmjopen-2016-015293. [42]LEELATHANALERK A,DONGTAI W,HUCKLEBERRY Y,et al.Evaluation of deprescribing amiodarone after new-onset atrial fibrillation in critical illness[J].Am J Med,2017,130(7):864-866.DOI:10.1016/j.amjmed.2017.02.025. [43]LINSKY A,METERKO M,STOLZMANN K,et al.Supporting medication discontinuation:provider preferences for interventions to facilitate deprescribing[J].BMC Health Serv Res,2017,17(1):447.DOI:10.1186/s12913-017-2391-0. [44]LINSKY A,SIMON S R,STOLZMANN K,et al.Patient perceptions of deprescribing:survey development and psychometric assessment[J].Med Care,2017,55(3):306-313.DOI:10.1097/MLR.0000000000000642. [45]LUYMES C H,BOELHOUWER N J,POORTVLIET R K,et al.Understanding deprescribing of preventive cardiovascular medication:a Q-methodology study in patients[J].Patient Prefer Adherence,2017,11:975-984.DOI:10.2147/PPA.S131625. [46]MALEK MAKAN A,VAN HOUT H,ONDER G,et al.Prevalence of preventive cardiovascular medication use in nursing home residents.room for deprescribing? The SHELTER study[J].J Am Med Dir Assoc,2017,18(12):1037-1042.DOI:10.1016/j.jamda.2017.06.022. [47]MARVIN V,WARD E,POOTS A J,et al.Deprescribing medicines in the acute setting to reduce the risk of falls[J].Eur J Hosp Pharm Sci Pract,2017,24(1):10-15.DOI:10.1136/ejhpharm-2016-001003. [48]MCINTYRE C,MCQUILLAN R,BELL C,et al.Targeted deprescribing in an outpatient hemodialysis unit:a quality improvement study to decrease polypharmacy[J].Am J Kidney Dis,2017,70(5):611-618.DOI:10.1053/j.ajkd.2017.02.374. [49]NG W L,TAN M Z W,KOH E Y L,et al.Deprescribing:what are the views and factors influencing this concept among patients with chronic diseases in a developed Asian community?[J].Proceedings of Singapore Healthcare,2017,26(3):172-179.DOI:10.1177/2010105817699633. [50]OBOH L,QADIR M S.Deprescribing and managing polypharmacy in frail older people:a patient-centred approach in the real world[J].Eur J Hosp Pharm Sci Pract,2017,24(1):58-62.DOI:10.1136/ejhpharm-2016-001008. [51]OHSHIMA S,HARA A,ABE T,et al.Deprescribing using the guidelines for medical treatment and its safety in the elderly and changes in patient QOL and activities of daily living[J].Yakugaku Zasshi,2017,137(5):623-633.DOI:10.1248/yakushi.16-00263. [52]SIROIS C,OUELLET N,REEVE E.Community-dwelling older people's attitudes towards deprescribing in Canada[J].Res Social Adm Pharm,2017,13(4):864-870.DOI:10.1016/j.sapharm.2016.08.006. [53]TURNER J P,TANNENBAUM C.Older adults' awareness of deprescribing:a population-based survey[J].J Am Geriatr Soc,2017,65(12):2691-2696.DOI:10.1111/jgs.15079. [54]WALLIS K A,ANDREWS A,HENDERSON M.Swimming against the tide:primary care physicians' views on deprescribing in everyday practice[J].Ann Fam Med,2017,15(4):341-346.DOI:10.1370/afm.2094. [55]ALRASHEED M M,ALHAWASSI T M,ALANAZI A,et al.Knowledge and willingness of physicians about deprescribing among older patients:a qualitative study[J].Clin Interv Aging,2018,13:1401-1408.DOI:10.2147/CIA.S165588. [56]BIEN B,BIEN-BARKOWSKA K.Prescribing or deprescribing in older persons:what are the real?life concerns in geriatric practice?[J].Polish Archives of Internal Medicine,2018,128(4):200-208.DOI:10.20452/pamw.4206. [57]BJERRE L M,FARRELL B,HOGEL M,et al.Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia:evidence-based clinical practice guideline[J].Can Fam Physician,2018,64(1):17-27. [58]BLENKE A A,VAN MARUM R J,VERMEULEN WINDSANT-VAN DEN TWEEL A M,et al.Deprescribing in newly admitted psychogeriatric nursing facility patients[J].Consult Pharm,2018,33(6):331-338.DOI:10.4140/TCP.n.2018.331. [59]CHENOWETH L,JESSOP T,HARRISON F,et al.Critical contextual elements in facilitating and achieving success with a person-centred care intervention to support antipsychotic deprescribing for older people in long-term care[J].Biomed Res Int,2018,2018:7148515.DOI:10.1155/2018/7148515. [60]CHEONG S T,NG T M,TAN K T.Pharmacist-initiated deprescribing in hospitalised elderly:prevalence and acceptance by physicians[J].Eur J Hosp Pharm Sci Pract,2018,25(e1):e35-39.DOI:10.1136/ejhpharm-2017-001251. [61]DJATCHE L,LEE S,SINGER D,et al.How confident are physicians in deprescribing for the elderly and what barriers prevent deprescribing?[J].J Clin Pharm Ther,2018,43(4):550-555.DOI:10.1111/jcpt.12688. [62]FARRELL B,RICHARDSON L,RAMAN-WILMS L,et al.Self-efficacy for deprescribing:a survey for health care professionals using evidence-based deprescribing guidelines[J].Res Social Adm Pharm,2018,14(1):18-25.DOI:10.1016/j.sapharm.2017.01.003. [63]GILLESPIE R,MULLAN J,HARRISON L.Deprescribing for older adults in Australia:factors influencing GPs[J].Aust J Prim Health,2018,24(6):463-469.DOI:10.1071/PY18056. [64]GULLA C,FLO E,KJOME R L,et al.Deprescribing antihypertensive treatment in nursing home patients and the effect on blood pressure[J].J Geriatr Cardiol,2018,15(4):275-283.DOI:10.11909/j.issn.1671-5411.2018.04.011. [65]KOMAGAMINE J,SUGAWARA K,HAGANE K.Characteristics of elderly patients with polypharmacy who refuse to participate in an in-hospital deprescribing intervention:a retrospective cross-sectional study[J].BMC Geriatr,2018,18(1):96.DOI:10.1186/s12877-018-0788-1. [66]KORENVAIN C,MACKEIGAN L,DAINTY K,et al.Exploring deprescribing opportunities for community pharmacists:protocol for a qualitative study[J].Can Pharm J(Ott),2018,151(4):228-232.DOI:10.1177/1715163518778301. [67]LUYMES C H,POORTVLIET R K E,VAN GELOVEN N,et al.Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study:a cluster randomised non-inferiority trial[J].BMC Med,2018,16(1):5.DOI:10.1186/s12916-017-0988-0. [68]MARTIN P,TANNENBAUM C.A prototype for evidence-based pharmaceutical opinions to promote physician-pharmacist communication around deprescribing[J].Can Pharm J(Ott),2018,151(2):133-141.DOI:10.1177/1715163518755813. [69]NADARAJAN K,BALAKRISHNAN T,MEILING Y E,et al.The attitudes and beliefs of doctors towards deprescribing medications[J].Proceedings of Singapore Healthcare,2018,27(1):41-48.DOI:10.1177/2010105817719711. [70]PETERSEN A W,SHAH A S,SIMMONS S F,et al.Shed-MEDS:pilot of a patient-centered deprescribing framework reduces medications in hospitalized older adults being transferred to inpatient postacute care[J].Ther Adv Drug Saf,2018,9(9):523-533.DOI:10.1177/2042098618781524. [71]POTTIE K,THOMPSON W,DAVIES S,et al.Deprescribing benzodiazepine receptor agonists:evidence-based clinical practice guideline[J].Can Fam Physician,2018,64(5):339-351. [72]PRUSKOWSKI J,ZAROWITZ B J,HANDLER S M.Perceptions of nursing facility providers on the utility of deprescribing[J].Consult Pharm,2018,33(7):386-402.DOI:10.4140/TCP.n.2018.386. [73]TEGEGN H G,TEFERA Y G,ERKU D A,et al.Older patients' perception of deprescribing in resource-limited settings:a cross-sectional study in an Ethiopia university hospital[J].BMJ Open,2018,8(4):e020590.DOI:10.1136/bmjopen-2017-020590. [74]VAN MIDDELAAR T,IVENS S D,VAN PEET P G,et al.Prescribing and deprescribing antihypertensive medication in older people by Dutch general practitioners:a qualitative study[J].BMJ Open,2018,8(4):e020871.DOI:10.1136/bmjopen-2017-020871. [75]ZHANG Y Z,TURNER J P,MARTIN P,et al.Does a consumer-targeted deprescribing intervention compromise patient-healthcare provider trust?[J].Pharmacy(Basel),2018,6(2):E31.DOI:10.3390/pharmacy6020031. [76]曾英彤,杨敏,伍俊妍,等.药学服务新模式——处方精简(Deprescribing)[J].今日药学,2017,27(6):390-393. [77]REEVE E,SHAKIB S,HENDRIX I,et al.The benefits and harms of deprescribing[J].Med J Aust,2014,201(7):386-389. [78]STEEL N,ABDELHAMID A,STOKES T,et al.A review of clinical practice guidelines found that they were often based on evidence of uncertain relevance to primary care patients[J].J Clin Epidemiol,2014,67(11):1251-1257.DOI:10.1016/j.jclinepi.2014.05.020. [79]American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults[J].J Am Geriatr Soc,2015,63(11):2227-2246.DOI:10.1111/jgs.13702. [80]O'MAHONY D,O'SULLIVAN D,BYRNE S,et al.STOPP/START criteria for potentially inappropriate prescribing in older people:version 2[J].Age Ageing,2015,44(2):213-218.DOI:10.1093/ageing/afu145. [81]中国老年保健医学研究会老年内分泌与代谢病分会,中国毒理学会临床毒理专业委员会.老年人多重用药安全管理专家共识[J].中国全科医学,2018,21(29):3533-3544.DOI:10.12114/j.issn.1007-9572.2018.00.225. [82]JOSEPH-WILLIAMS N,LLOYD A,EDWARDS A,et al.Implementing shared decision making in the NHS:lessons from the MAGIC programme[J].BMJ,2017,357:j1744.DOI:10.1136/bmj.j1744. [83]GARFINKEL D,ZUR-GIL S,BEN-ISRAEL J.The war against polypharmacy:a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people[J].Isr Med Assoc J,2007,9(6):430-434. [84]GARFINKEL D,MANGIN D.Feasibility study of a systematic approach for discontinuation of multiple medications in older adults:addressing polypharmacy[J].Arch Intern Med,2010,170(18):1648-1654.DOI:10.1001/archinternmed.2010.355. [85]GARCíA-GOLLARTE F,BALERIOLA-JúLVEZ J,FERRERO-LóPEZ I,et al.An educational intervention on drug use in nursing homes improves health outcomes resource utilization and reduces inappropriate drug prescription[J].J Am Med Dir Assoc,2014,15(12):885-891.DOI:10.1016/j.jamda.2014.04.010. [86]PITK?L? K H,JUOLA A L,KAUTIAINEN H,et al.Education to reduce potentially harmful medication use among residents of assisted living facilities:a randomized controlled trial[J].J Am Med Dir Assoc,2014,15(12):892-898.DOI:10.1016/j.jamda.2014.04.002. [87]GNJIDIC D,LE COUTEUR D G,KOULADJIAN L,et al.Deprescribing trials:methods to reduce polypharmacy and the impact on prescribing and clinical outcomes[J].Clin Geriatr Med,2012,28(2):237-253.DOI:10.1016/j.cger.2012.01.006. [88]GRAVES T,HANLON J T,SCHMADER K E,et al.Adverse events after discontinuing medications in elderly outpatients[J].Arch Intern Med,1997,157(19):2205-2210. [89]VAN DER WARDT V,HARRISON J K,WELSH T,et al.Withdrawal of antihypertensive medication:a systematic review[J].J Hypertens,2017,35(9):1742-1749.DOI:10.1097/HJH.0000000000001405. [90]BLACK D M,SCHWARTZ A V,ENSRUD K E,et al.Effects of continuing or stopping alendronate after 5 years of treatment:the Fracture Intervention Trial Long-term Extension(FLEX):a randomized trial[J].JAMA,2006,296(24):2927-2938.DOI:10.1001/jama.296.24.2927. |
[1] | 冯晓玉, 李婉玲, 吕思漫, 倪翠萍, 王浩成, 刘宇. 基于文献计量学的interRAI家庭护理评估工具国际研究现状及热点分析[J]. 中国全科医学, 2023, 26(34): 4351-4358. |
[2] | 顾晗昕, 刘洋, 刘远立. 政策工具视角下社区老年人跌倒干预国际比较研究[J]. 中国全科医学, 2023, 26(34): 4231-4238. |
[3] | 王越, 陈晴, 刘鲁蓉. 中国老年人抑郁检出率及影响因素的Meta分析[J]. 中国全科医学, 2023, 26(34): 4329-4335. |
[4] | 徐健, 戴芳芳, 潘文雷, 黄倩, 陆萍, 王剑峰, 贾环, 杨宇琪, 黄蛟灵. "健康中国"背景下我国社区中医药服务研究热点和前沿趋势的可视化分析[J]. 中国全科医学, 2023, 26(34): 4343-4350. |
[5] | 余新艳, 赵珺, 赵晓晔, 姜清茹, 陈雅田, 王艳, 张海澄. 移动智慧医疗在基层老年慢性病患者心血管病防控中的应用研究[J]. 中国全科医学, 2023, 26(33): 4167-4172. |
[6] | 辛功恺, 丛欣, 袁磊, 程悦彤, 倪翠萍, 张巍巍, 張平平, 刘宇. 失智症老年人综合评估工具的研究进展[J]. 中国全科医学, 2023, 26(33): 4103-4109. |
[7] | 张帅, 李琴, 李东锋, 肖金平, 李云鹏. 使用固体燃料与中国老年人高血压发病风险的前瞻性队列研究[J]. 中国全科医学, 2023, 26(32): 4001-4006. |
[8] | 陈希, 章娟, 李霖, 张佳琪, 吴耀丽, 郭慧, 王超群. 中国中老年人体力活动与全因死亡风险的关系:前瞻性队列研究[J]. 中国全科医学, 2023, 26(31): 3890-3895. |
[9] | 王敏, 郭文军, 陈永真, 凤心雨, 汤忠泉, 赵晓敏, 欧婷, 戴昕妤, 李云涛. 基于Web of Science数据库的未分化疾病文献计量学和可视化分析[J]. 中国全科医学, 2023, 26(31): 3930-3938. |
[10] | 张鹏, 高鹰, 杨洪喜, 万春晓. 中国长寿地区老年人血尿酸水平与慢性肾脏病发病风险研究[J]. 中国全科医学, 2023, 26(31): 3884-3889. |
[11] | 段妍琴, 彭颖, 刘胜兰, 刘海姣, 杨慧琼, 胡海清. 门诊老年患者潜在不适当用药情况及影响因素分析[J]. 中国全科医学, 2023, 26(31): 3902-3907. |
[12] | 张明, 许静, 孙振华, 赵文浩, 马樱倩, 张建桥, 沈海萍. 图像引导的光动力治疗改善老年重度梗阻食管癌患者营养状况的研究[J]. 中国全科医学, 2023, 26(30): 3780-3784. |
[13] | 周小琦, 刘新会, 张微, 李长风, 严亚琼. 老年人丙氨酸氨基转移酶和天冬氨酸氨基转移酶/丙氨酸氨基转移酶与2型糖尿病及代谢综合征的相关性研究[J]. 中国全科医学, 2023, 26(29): 3645-3649. |
[14] | 周思静, 罗邦安, 曹慧, 张熙, 王东欣. ≥65岁居民老年痴呆流行病学特征及其与慢性病共病的相关性研究[J]. 中国全科医学, 2023, 26(29): 3616-3621. |
[15] | 王萧冉, 张丹. 慢性病共病对我国老年人焦虑症状的影响研究:基于倾向性评分匹配[J]. 中国全科医学, 2023, 26(29): 3622-3627. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||